182 related articles for article (PubMed ID: 8763345)
1. MDR1/P-glycoprotein in haematological neoplasms.
Marie JP; Zhou DC; Gurbuxani S; Legrand O; Zittoun R
Eur J Cancer; 1996 Jun; 32A(6):1034-8. PubMed ID: 8763345
[No Abstract] [Full Text] [Related]
2. Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies.
Sonneveld P
Eur J Cancer; 1996 Jun; 32A(6):1062-9. PubMed ID: 8763348
[No Abstract] [Full Text] [Related]
3. Is p-glycoprotein a potential target for reversing clinical drug resistance?
Dalton WS
Curr Opin Oncol; 1994 Nov; 6(6):595-600. PubMed ID: 7827171
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological considerations in the modulation of multidrug resistance.
Fisher GA; Lum BL; Hausdorff J; Sikic BI
Eur J Cancer; 1996 Jun; 32A(6):1082-8. PubMed ID: 8763350
[No Abstract] [Full Text] [Related]
5. Reversal of multidrug resistance in hematological malignancies.
Vossebeld PJ; Sonneveld P
Blood Rev; 1999 Jun; 13(2):67-78. PubMed ID: 10414943
[No Abstract] [Full Text] [Related]
6. Diagnosis and reversal of multidrug resistance in paediatric cancers.
Chan HS; Grogan TM; DeBoer G; Haddad G; Gallie BL; Ling V
Eur J Cancer; 1996 Jun; 32A(6):1051-61. PubMed ID: 8763347
[No Abstract] [Full Text] [Related]
7. P-glycoprotein--a mediator of multidrug resistance in tumour cells.
Germann UA
Eur J Cancer; 1996 Jun; 32A(6):927-44. PubMed ID: 8763334
[No Abstract] [Full Text] [Related]
8. Biology of the multidrug resistance-associated protein, MRP.
Loe DW; Deeley RG; Cole SP
Eur J Cancer; 1996 Jun; 32A(6):945-57. PubMed ID: 8763335
[No Abstract] [Full Text] [Related]
9. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
[TBL] [Abstract][Full Text] [Related]
10. Specificity and sensitivity of immunocytochemistry for detecting P-glycoprotein in haematological malignancies.
Gala JL; McLachlan JM; Bell DR; Michaux JL; Ma DD
J Clin Pathol; 1994 Jul; 47(7):619-24. PubMed ID: 7916349
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance: clinical relevance in haematological malignancies.
Kaye SB; Kerr DJ
Blood Rev; 1991 Mar; 5(1):38-41. PubMed ID: 1674435
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of the P-glycoprotein, the multidrug transporter.
Stein WD
Exp Physiol; 1998 Mar; 83(2):221-32. PubMed ID: 9568482
[No Abstract] [Full Text] [Related]
13. Alternative (non-P-glycoprotein) mechanisms of drug resistance in non-Hodgkin's lymphoma.
Dalton WS
Hematol Oncol Clin North Am; 1997 Oct; 11(5):975-86. PubMed ID: 9336726
[TBL] [Abstract][Full Text] [Related]
14. Transporter molecules in multidrug resistance.
Scheper RJ; Scheffer GL; Flens MJ; van der Valk P; Broxterman HJ; Izquierdo MA
Cytotechnology; 1996; 19(3):187-90. PubMed ID: 8862005
[No Abstract] [Full Text] [Related]
15. How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein.
Broxterman HJ; Lankelma J; Pinedo HM
Eur J Cancer; 1996 Jun; 32A(6):1024-33. PubMed ID: 8763344
[No Abstract] [Full Text] [Related]
16. P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells.
Licht T; Pastan I; Gottesman M; Herrmann F
Ann Hematol; 1994 Oct; 69(4):159-71. PubMed ID: 7948302
[TBL] [Abstract][Full Text] [Related]
17. Multifactorial drug-resistance phenomenon in acute leukemias: impact of P170-MDR1, LRP56 protein, glutathione-transferases and metallothionein systems on clinical outcome.
Goasguen JE; Lamy T; Bergeron C; Ly Sunaram B; Mordelet E; Gorre G; Dossot JM; Le Gall E; Grosbois B; Le Prisé PY; Fauchet R
Leuk Lymphoma; 1996 Nov; 23(5-6):567-76. PubMed ID: 9031088
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein: its role in drug resistance.
Ling V
Am J Med; 1995 Dec; 99(6A):31S-34S. PubMed ID: 8585532
[No Abstract] [Full Text] [Related]
19. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers.
Ford JM
Eur J Cancer; 1996 Jun; 32A(6):991-1001. PubMed ID: 8763340
[No Abstract] [Full Text] [Related]
20. Molecular diagnosis of multidrug resistance.
Herzog CE; Bates SE
Cancer Treat Res; 1994; 73():129-47. PubMed ID: 7710903
[No Abstract] [Full Text] [Related]
[Next] [New Search]
